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Background: Numerous studies on animals evidenced that conjugated linoleic acid (CLA) could decrease blood
pressure (BP) in several rat models. However, such beneficial effect is not completely supported by studies on
humans.
Methods: We searched the Pubmed, Cochrane Library, and the ClinicalTrials.gov databases for relevant randomized,
double-blind placebo-controlled trials up to August 2014 to perform a meta-analysis. A random-effects model was
used to calculate the combined treatment effects.
Results: Eight studies with nine trials, which involved 638 participants with CLA supplementation ranging from
2.0 g/day to 6.8 g/day, were included in this meta-analysis. Compared with placebo, the pooled estimate of change
was −0.03 mm Hg (95% CI: −2.29, 2.24, P = 0.98) and 0.69 mm Hg (95% CI: −1.41, 2.80, P = 0.52) in systolic and diastolic
BPs, respectively. No significant heterogeneity across studies for systolic BP; however, substantial heterogeneity for
diastolic BP was identified. Publication bias was not found for both systolic and diastolic BPs.
Conclusion: The findings of this meta-analysis did not support the overall favorable effect of CLA supplementation on
BP regulation.
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Conjugated linoleic acid (CLA) is a mixture of positional
and geometric isomers of linoleic acid, an 18-carbon
polyunsaturated fatty acid. CLA isomers are naturally
occurring fatty acids identified in ruminant animals. The
most commonly studied CLA isomers are the cis (c)9,
trans (t)11 and the t10, c12-CLA isomers [1]. In general,
commercial CLA supplements usually equally contain
these two active isomers, whereas, CLA in dairy prod-
ucts consists over 90% of c9, t11-CLA isomer [2].
Trans fatty acid may adversely influence human health;
yet, evidence has shown that CLA exerts many beneficial
effects, such as anti-obesity, anti-diabetic and anti-
inflammatory properties [3]. Of note, CLA was also* Correspondence: qinliqiang@suda.edu.cn
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unless otherwise stated.found to lower blood pressure (BP) among various rat
models [4-8]. A possible mechanism by which CLA
might influence BP could be through endothelial func-
tion, NO production and eicosanoids production [8,9].
In this regard, CLA may also influence BP of humans.
Several human studies demonstrated that CLA supple-
mentation can lower BP [10-13]; however, others showed
no significant BP-lowering effect [14-21]. These incon-
sistent findings may result from variation in sample size,
study population, or study quality. Thus, the present
study aimed to systematically examine the effect of CLA
supplementation on BP by conducting a meta-analysis of
randomized controlled trials (RCTs) designed by double-
blind and placebo.Materials and methods
Search strategy
We followed the Preferred Reporting Items for System-
atic Reviews and Meta-analysis (PRISMA) guidelines inhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Pubmed, Cochrane library and the ClinicalTrials.gov (n=79)
Excluded by abstracts and titles (n=65)
Potentially relevant studies for further full-text screening (n=14)
Incorporated CLA as part of the 
active components (n=4)
Adopted an RCT with no 
double-blind design (n=1)
Used a cross-over RCT design with 
short intervention duration (n=1)
Included Eight studies with nine trials
Separately determined 
BP in overweight and 
obese subjects (n=1)
Figure 1 Flow chart of study selection.
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Pubmed, Cochrane library and the ClinicalTrials.gov da-
tabases through August 2014 for relevant studies, using
terms of “conjugated linoleic acid” or “CLA” in combin-
ation with “blood pressure” or “hypertension”. No re-
striction was imposed. In addition, we carried out a
manual search using reference lists of original articles
and recent reviews.
Study selection
Studies were included if they 1) were randomized,
double-blind placebo-controlled trials in adults (Age ≥
18 years old); 2) CLA was the only active intervention in
treatment group; 3) had intervention duration ≥ 4 weeks;
4) had a control or a comparison group; 5) included the
net changes of systolic and/or diastolic blood pressure
(SBP/DBP) and their corresponding standard deviation
(SD) or available data to calculate these values.
Data extraction
The data were extracted independently by two re-
searchers in duplicate (J Yang, HP Wang) according to
the described selection criteria using an electronic form.
Disagreement was resolved by discussion with the third
research (LQ Qin). The following data were extracted
from study: first author’s name, publication year, study
design, intervention method, study period, sample size,
daily dose of CLA (c9, t11 and t10, c12 isomers). We
also extracted the following participant characteristics:
gender, mean age, body mass index (BMI), baseline SBP/
DBP and their changes of each study. Study quality was
assessed by a modified Jadad Scale [23], where total
score ranges 0 to 7 points based on their description of
randomization, concealment of allocation, double blind-
ing, withdrawn or drop-outs explanation.
Statistical methods
The net changes were calculated as the difference be-
tween the baseline and final values of BP. If only SD for
the baseline and final values were provided, SD for the
net changes were imputed according to the method of
Follmann using a correlation coefficient of 0.5 [24].
Overall effect size was expressed as weighted mean dif-
ference (WMD) with 95% confidence interval (CI) using
Stata11 (StataCorp, College Station, TX, USA). The het-
erogeneity between the studies was tested using the Q
test at the P < 0.10 level of significance and quantified by
the I2statistic, which describes the inconsistency across
studies [25]. In general, the random-effects model was
used in the presence of significant heterogeneity. In fact,
heterogeneity always exists in varying degrees. Thus, re-
sults from random effects model, which would be more
conservative (and hence more appropriate), were pre-
sented in our meta-analysis. We did not conductsubgroup analysis because of the small number of trials.
Rather, we performed a sensitivity analysis, in which a
single trial was omitted each time and the effect size was
recalculated to investigate its influence on the overall ef-
fect size. Furthermore, we conducted meta-regression
analysis to explore possible sources of heterogeneity
across studies. To minimize the likelihood of false-
positive results, we carefully selected a few covariates,
including CLA dose, intervention duration and baseline
BP. Potential publication bias was assessed using the
Begg’s funnel plots and Egger’s regression test [26]. A




A flow chart of literature search and study selection is
presented in Figure 1. A total of 79 potential relevant ar-
ticles and 14 trials were retrieved for further assessment.
Six of these studies, however, were excluded from the
analysis because four of them [11,13,27,28] incorporated
CLA as part of the active components in treatment
group, one adopted an RCT with no double-blind design
[19], and the other one used a cross-over RCT design
with short intervention duration (3 weeks) [20]. Mean-
while, one study separately determined BP in overweight
and obese subjects and was considered as two trials [16].
Finally, eight studies with nine trials were included in
this meta-analysis [10,12,14-18,21].
Study characteristics
The characteristics of the included studies are presents
in Table 1. These studies were published from 2000 to
2013, in which five were conducted in Europe, two in
Iran, and one in Japan. Sample sizes varied from 38 to
346 with a sum of 318 in the CLA groups and 320 in
the control groups. In five studies, both men and women
Table 1 Characteristic of the trials and participants in this meta-analysis














Berven 2000 Norway 25/22 47.1 63.8 29.7 139.7/85.7 2.65 (1.33) olive oil 12 5
Raff 2006 Denmark 18/20 25.9 100 22.3 119.5/61.6 4.7 (2.35) Control diet 5 4
Taylor 2006 UK 21/19 46 100 33.0 124.9/82.4 3.2 (1.62) olive oil 12 6
Iwata 2007 Japan 20/20 41.5 100 28.0 127.5/77.1 6.8 (3.4) safflower oil 12 6
Laso 2007 Spain 10/11a 10/13b 53.9 75.0 27.6a 33.1b 145.5/82.5a 148.5/86.0b 3 (1.5) Skimmed milk 12 4
Aryaeian 2008 Iran 22/22 47.1 13.6 27.8 119.8/73.5 2 (1) oleic sunflower 12 5
Sluijs 2010 Netherland 173/173 58.4 48.3 27.9 127.4/76.1 3.1 (0.6) palm oil 24 7
Shadman 2013 Iran 19/20 45.3 46.2 27.2 122.6/81.2 3 (1.5) Soybean oil 8 4
aOverweight participants; bObese participants; cAmount of t10, c12-CLA is presented in parentheses.
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studies included only men. Except for the study of Raff
that involved apparently healthy adults [14], the others
included overweight and obese adults (BMI ≥ 25 kg/m2).
No study specified the hypertension status of partici-
pants, which the majority were normotensive as indi-
cated by mean BP levels at baseline. Two trials were
conducted in patients with rheumatoid arthritis and type
2 diabetes mellitus, respectively [17,21]. Dose of CLA
varied from 2 g/day to 6.8 g/day, with a median of 3 g/d.
All studies supplemented CLA with a mixture of iso-
mers, and 50:50 isomer blends were used except in the
study of Sluijs [18]. Only one trial had full Jadad score
(=7). Tree trials had relatively low Jadad score (=4). On
the other hand, two studies performed intention-to-treat
analysis. Intervention duration lasted from 5 weeks to












Figure 2 Meta-analysis of the effect of conjugated linoleic acid suppl
WMD, weighted mean difference.Effect of CLA on BP
Compared with placebo, CLA supplementation was asso-
ciated with an average net change ranging from −11.82 to
4.00 mm Hg for SBP and from −7.22 to 6.00 mm Hg for
DBP. SBP and DBP reductions were statistically significant
in only one trial [17], whereas the other trial observed a
significant DBP increase [14]. The pooled estimate of
change in SBP was −0.03 mm Hg (95% CI: −2.29, 2.24;
P = 0.98), without significant heterogeneity (I2 = 22.2%,
P = 0.25) (Figure 2). Meanwhile, the pooled estimate of
change in DBP was 0.69 mm Hg (95% CI: −1.41, 2.80;
P = 0.52), with substantial heterogeneity across trials
(I2 = 52.0%, P = 0.03) (Figure 3). Thus, there was no
overall effect of CLA supplementation on both SBP and
DBP. Such supplementation even elevated DBP without
significance. Neither Begg’s test nor Egger’s test pro-
























ementation on systolic blood pressure as compared with control.



































Figure 3 Meta-analysis of the effect of conjugated linoleic acid supplementation on diastolic blood pressure as compared with control.
WMD, weighted mean difference.
Table 2 Characteristics associated with net change in
blood pressure: univariate meta-analysis analysis
Systolic BP Diastolic BP
Coefficient (95% CI) P Coefficient (95% CI) P
Baseline BP −0.11 (−0.53, 0.30) 0.54 −0.23 (−0.61, 0.14) 0.13
Dose −1.78 (−3.76, 0.20) 0.07 −1.32 (−3.20, 0.56) 0.14
Duration −0.16 (−0.53, 0.20) 0.32 −0.19 (−0.61, 0.23) 0.32
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Additional analyses examining the influence of an indi-
vidual trial on the overall effect size by omitting one
trial in each turn yielded a range from 0.22 mm Hg
(95% CI: −1.45, 1.90) to–0.27 mm Hg (95% CI:-2.83,
2.29) and from 0.92 mm Hg (95% CI:-1.45, 3.28) to-
0.06 mm Hg (95% CI:-1.20, 1.08) for SBP and DBP, re-
spectively. None of the individual studies appeared to
have appreciable impacts on the overall combined ef-
fect sizes.
Meta-regression analyses
Meta-regression analysis was subsequently conducted to
assess whether BP change is related to CLA dose, inter-
vention duration, or baseline BP levels. The results of
the analysis revealed that none of these covariates had
significant influences on the overall effect sizes (Table 2).
However, a trend toward greater reductions in SBP among
subjects with higher CLA dose (r = −1.78, P =0.07) was
observed.
Discussion
Hypertension significantly contributes to the morbidity
and mortality associated with cardiovascular disease. In
this event, hypertension must necessarily be prevented.
Nevertheless, this meta-analysis of randomized, double-
blind, placebo-controlled trials found that supplemental
CLA does not affect human BP regulation.
In particular, the results of this analysis contradict
those of the animal studies, which consistently reported
the BP lowering effects of CLA [4-8]. Such discrepancy
between human and animal studies may because of the
characteristics of observational subjects as animalmodels already have established hypertension. In the
studies including in this meta-analysis, most participants
were generally normotensive, in which further decreas-
ing BP was not probable. To surprise, the study of Laso
with a relatively higher BP (SBP > 130 mmHg or DBP >
85 mmHg) also did not observe BP change for supple-
mentation with 3 g of CLA for 12 weeks [16]. Two hu-
man trials reported BP lowering effects of CLA. Herrera
discovered that CLA combined with calcium could re-
duce pregnancy-induced hypertension [11]. Zhao identi-
fied that CLA supplementation could enhance the
antihypertensive effects of Ramipril among stage 1
hypertension patients [13]. The participants in these two
studies were hypertensive, further suggesting the import-
ance of baseline BP for CLA effect. These two studies
were excluded in the current meta-analysis because they
did not satisfy the selection criteria.
Obesity is a major factor that promotes hypertension.
Participants were mostly overweight or obese adults in
this meta-analysis. An animal study demonstrated that
CLA could reduce the number of large adipocytes,
thereby contributing to obesity-related hypertension [7].
In study of Laso, the participants were divided into two
groups according to their BMI. Surprisingly, CLA
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overweight participants, but not in obese [16]. As de-
scribed above, no change of BP was observed in this
population. In fact, elevated BP after CLA supplementa-
tion was observed in the study of Raff, where the partici-
pants had relatively low BMI [14].
CLA dose is another relevant factor of BP regulation.
Meta-regression analyses found a trend toward greater
reduction in SBP among participants with higher CLA
dose. In most animal experiments, the daily intake of
0.55 to 1% of CLA is attributed to nearly all of the bene-
ficial effects of CLA [29]. Plasma CLA concentration can
reach 200 mM in the rodent animals followed by dietary
intakes of 0.5% CLA [30]. If plasma CLA concentration
was taken as a reference parameter, the daily intake of
3.2 g of CLA in humans must attain the comparable
level [31]. Most of the studies in this meta-analysis
reached this particular CLA dose. Hence, beneficial ef-
fect was expected to be observed in humans. Contrarily,
no BP lowering effect was identified in these studies.
Thus, apart from CLA dose, different mixture of isomers
must also be considered. Divergent effects of c9, t11 and
t10, c12 isomers on BP were observed in animal studies
when these two isomers were separately used [4,7].
Interestingly, t10, c12, not c9, t11 isomer, significantly
suppressed the development of hypertension [4]. The
different effects of c9, t11 and t10, c12 isomers were also
reported on blood lipid and insulin resistance in human
research [32,33]. However, this meta-analysis did not in-
volve human studies that observed the separated isomer
of CLA on BP. In study of Iwata, the contents of t10,
c12 and c9, t11 isomers were both 3.4 g, which was the
highest measure among all studies. Although BP was sig-
nificantly deceased at 12 weeks than at the baseline, BP
was simultaneously decreased in the control group,
resulting in no beneficial effect of CLA [12].
Several limitations of this meta-analysis must be ac-
knowledged. First, only nine randomized trials were in-
cluded; thus, subgroup analyses were planned, but not
performed. Such analyses stratified by location, interven-
tion duration, or study design might be informative, yet
they would have increased the risk of type I errors. Sec-
ond, most studies included in this meta-analysis were
not primarily designed to investigate the CLA effect on
BP. Thus, factors related with BP were maybe vague,
such as intentional lifestyle or behavioral change,
method to measure BP. Third, food intake was not con-
trolled in several studies, and the participants may pos-
sibly consumed extra CLA from diet source. However,
the daily intake of CLA in ruminant products was esti-
mated 152 and 212 mg in women and men, respectively
[34]. Theses measures can be neglected in relatively
higher CLA supplementation. Finally, substantial hetero-
geneity across trials in DBP was determined. In thismeta-analysis, random effects model was used to esti-
mate the overall effect size.
Our study had some strengths. Because individual
studies had insufficient statistical power, our meta-
analysis enhanced the power to detect a possible associ-
ation and provided more reliable estimates. All included
studies were randomized, double-blind, placebo-
controlled trials, which minimized biases and suggested
a high internal validity. In addition, results of sensitivity
analyses supported the robustness of the findings. Fi-
nally, publication bias, the selective reporting of studies
featuring positive or extreme results, may result in over-
estimation of relationship between CLA and BP. How-
ever, no publication bias was found in this meta-analysis.
On the basis of the current evidence, the findings of
this work do not support the overall favorable effect of
CLA supplementation on BP regulation. Whether the ef-
fects of CLA on BP are related to baseline BP, obese sta-
tus, and intervention dose or duration is yet to be
determined. Further studies must be accumulated for
subgroup analysis according to the above characteristics
and study design.
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